For decades scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen.

Researchers identified bemnifosbuvir as a potential treatment for hepatitis E, finding that it inhibited viral replication in ...

A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating.

A public health emergency is about to emerge because of federal ADAP (AIDS Drug Assistance Program) funding cuts. Long since ...

In a new study published in Science Translational Medicine, investigators have shown that HIV can acquire mutations that cause resistance to lenacapavir—but at a huge cost to the virus itself.

For people living with human immunodeficiency virus (HIV), antiretroviral therapy prevents HIV-infected immune cells from replicating the virus to protect against illness and transmission. Inactive ...

Although existing treatments allow a full life with the HIV virus, now, more than ever, scientists are close to developing a mechanism that will completely remove the virus from the body.

Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.

A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating. Around 70,000 people die each year from infections with the hepatitis E virus.

Chronic hepatitis D virus (HDV) coinfection in people with chronic hepatitis B is associated with rapid progression to liver ...

With NIH funding, the group will pursue research and patient care approaches for a disease that affects more than 250 million people around the globe ...

The Johns Hopkins Medicine-led, multinational Hepatitis B and HIV Cure Consortium, colloquially known as the BICC, was recently established through ...